Intravitreal VEGF-inhibitors: is Avastin® a generic substitute for Lucentis®?
نویسندگان
چکیده
منابع مشابه
Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).
Corneal avascularity is necessary for the preservation of optimal vision. The cornea maintains a dynamic balance between pro- and antiangiogenic factors that allows it to remain avascular under normal homeostatic conditions; however, corneal avascularity can be compromised by pathologic conditions that negate the cornea's "angiogenic privilege." The clinical relevance of corneal neovascularizat...
متن کاملIntravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review.
PURPOSE OF REVIEW We conducted a systematic review to evaluate whether the existing evidence justifies the intravitreal use of bevacizumab in comparison to ranibizumab in age-related macular degeneration. RECENT FINDINGS Compared with photodynamic therapy, bevacizumab shows a relative improvement in visual acuity that is of similar size as in the comparison of ranibizumab with photodynamic th...
متن کاملIntravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review.
AIM To conduct a systematic review in order to compare adverse effects (AE) and the reporting of harm in randomised controlled trials (RCTs) and non-RCTs evaluating intravitreal ranibizumab and bevacizumab in age-related macular degeneration. METHODS Medline, Embase and the Cochrane Library were searched with no limitations of language and year of publication. Studies which compared bevacizum...
متن کاملCanadian Health Policy
Anti-VEGF Drugs Anti-VEGF drugs are used to treat retinal conditions such as the wet form of age-related macular degeneration (wAMD) which is responsible for 80-90% of the vision loss associated with AMD. Avastin, Lucentis and Eylea are anti-VEGF drugs. Avastin was developed as a systemic treatment for cancer. It was also considered for retinal conditions, but evidence showed that systemic expo...
متن کاملIntravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy.
PURPOSE To report on intravitreal bevacizumab treatment for external beam radiation therapy (EBRT)-related radiation maculopathy. METHODS Three patients (4 eyes) with EBRT-related maculopathy were treated with periodic (4- to 8-week) intravitreal injections of bevacizumab (1.25 mg in 0.05 cc). Outcome measures included best-corrected Early Treatment Diabetic Retinopathy Study visual acuity, r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Ophthalmologica Scandinavica
سال: 2007
ISSN: 1395-3907
DOI: 10.1111/j.1600-0420.2006.00869.x